A team of scientists from KTH Royal Institute of Technology and Karolinska Institutet has reported the development and characterization of a new class of small non-immunoglobulin affibody proteins that bind to the highly glycosylated human carcinoembryonic antigen-related adhesion molecule 5 (CEACAM5, CEA) with high affinity.
Simon Fraser University, TRIUMF and the University of British Columbia have disclosed radiolabeled compounds reported to be useful for the diagnosis of cancer.
A team of U.S. and South Korean researchers have developed an AI model called MSI-SEER that can not only predict microsatellite instability-high (MSI-H) tumors based on tissue slides, but also flag “what it does not know.” “Have you ever asked ChatGPT anything, and the response was, ‘I don’t know?’” Cheong Jae-ho asked during an interview with BioWorld. “Probably not, and that is the problem with AI now.”
Nanjing Nuoyuan Medical Devices Co. Ltd. has discovered drug conjugates comprising a fluorescent moiety targeting hepatocyte growth factor receptors (HGFR; MET) covalently linked to crizotinib through a linker. They are reported to be useful for diagnosis of liver and colon cancer.
IMU Biosciences Ltd. is working to transform society’s understanding of the immune system. The company’s platform maps the immune system at molecular, cellular and system levels, to unlock new insights into immune-related health and diseases, paving the way for clinical applications that could improve patient outcomes.
Lila Biologics Inc. has entered into a global licensing and multitarget research collaboration with Eli Lilly & Co. focused on the discovery, development and commercialization of novel radioligand therapies for imaging and treatment of solid tumors.
Technische Universität München has described conjugates comprising a silicone-based fluoride acceptor (SiFA)-based peptide targeting moiety covalently linked to radiolabeled chelating agents through a divalent linker.
Shanghai Fosun Pharmaceutical Industry Development Co. Ltd. has identified drug-conjugates comprising a radionuclide-labeled molecular probe linked to ligand targeting fibroblast activation protein α (FAP) through a linker reported to be useful for the treatment and diagnosis of cancer.
Hepatocellular carcinomas (HCCs) are challenging to diagnose due to the tumor heterogeneity and unnoticeable early symptoms. Researchers from Anhui Medical University have developed a novel gallium 68 (68Ga)-labeled radiotracer, named [68Ga]DOTA-AngII, designed to improve the precision of HCC imaging.
Deep learning tools for protein design can also be used to create molecules that bind to them. Certain peptides, such as intrinsically disordered proteins (IDPs), are challenging to target due to their variable nature. However, scientists from the lab of Nobel laureate David Baker have developed a method to generate binders for IDPs by searching the world’s largest protein database with their AI-powered tool RFdiffusion.
RSS
